Omeros Quick Ratio 2010-2024 | OMER
Historical quick ratio values for Omeros (OMER) over the last 10 years.
| Omeros Quick Ratio Historical Data |
| Date |
Current Assets - Inventory |
Current Liabilities |
Quick Ratio |
| 2024-12-31 |
$0.00B |
$0.08B |
0.00 |
| 2024-09-30 |
$0.00B |
$0.06B |
0.00 |
| 2024-06-30 |
$0.00B |
$0.06B |
0.00 |
| 2024-03-31 |
$0.00B |
$0.06B |
0.00 |
| 2023-12-31 |
$0.00B |
$0.05B |
0.00 |
| 2023-09-30 |
$0.00B |
$0.15B |
0.00 |
| 2023-06-30 |
$0.00B |
$0.14B |
0.00 |
| 2023-03-31 |
$0.00B |
$0.14B |
0.00 |
| 2022-12-31 |
$0.00B |
$0.14B |
0.00 |
| 2022-09-30 |
$0.00B |
$0.04B |
0.00 |
| 2022-06-30 |
$0.00B |
$0.04B |
0.00 |
| 2022-03-31 |
$0.00B |
$0.04B |
0.00 |
| 2021-12-31 |
$0.00B |
$0.05B |
0.00 |
| 2021-09-30 |
$0.09B |
$0.04B |
2.12 |
| 2021-06-30 |
$0.11B |
$0.05B |
2.34 |
| 2021-03-31 |
$0.13B |
$0.04B |
3.02 |
| 2020-12-31 |
$0.00B |
$0.04B |
0.00 |
| 2020-09-30 |
$0.19B |
$0.05B |
4.08 |
| 2020-06-30 |
$0.04B |
$0.04B |
0.97 |
| 2020-03-31 |
$0.08B |
$0.06B |
1.46 |
| 2019-12-31 |
$0.10B |
$0.06B |
1.85 |
| 2019-09-30 |
$0.06B |
$0.05B |
1.34 |
| 2019-06-30 |
$0.07B |
$0.04B |
1.59 |
| 2019-03-31 |
$0.08B |
$0.05B |
1.71 |
| 2018-12-31 |
$0.09B |
$0.04B |
2.40 |
| 2018-09-30 |
$0.07B |
$0.03B |
2.68 |
| 2018-06-30 |
$0.10B |
$0.02B |
3.94 |
| 2018-03-31 |
$0.08B |
$0.03B |
3.19 |
| 2017-12-31 |
$0.11B |
$0.03B |
4.10 |
| 2017-09-30 |
$0.12B |
$0.03B |
4.74 |
| 2017-06-30 |
$0.05B |
$0.03B |
2.11 |
| 2017-03-31 |
$0.05B |
$0.02B |
2.97 |
| 2016-12-31 |
$0.06B |
$0.02B |
3.68 |
| 2016-09-30 |
$0.06B |
$0.02B |
3.69 |
| 2016-06-30 |
$0.03B |
$0.02B |
2.01 |
| 2016-03-31 |
$0.02B |
$0.02B |
1.28 |
| 2015-12-31 |
$0.04B |
$0.02B |
2.26 |
| 2015-09-30 |
$0.04B |
$0.02B |
1.75 |
| 2015-06-30 |
$0.06B |
$0.02B |
2.79 |
| 2015-03-31 |
$0.07B |
$0.02B |
3.61 |
| 2014-12-31 |
$0.01B |
$0.02B |
0.46 |
| 2014-09-30 |
$0.00B |
$0.01B |
0.00 |
| 2014-06-30 |
$0.00B |
$0.01B |
0.00 |
| 2014-03-31 |
$0.00B |
$0.01B |
0.00 |
| 2013-12-31 |
$0.00B |
$0.01B |
0.00 |
| 2013-09-30 |
$0.00B |
$0.01B |
0.00 |
| 2013-06-30 |
$0.00B |
$0.01B |
0.00 |
| 2013-03-31 |
$0.00B |
$0.01B |
0.00 |
| 2012-12-31 |
$0.00B |
$0.01B |
0.00 |
| 2012-09-30 |
$0.00B |
$0.02B |
0.00 |
| 2012-06-30 |
$0.00B |
$0.02B |
0.00 |
| 2012-03-31 |
$0.00B |
$0.02B |
0.00 |
| 2011-12-31 |
$0.00B |
$0.02B |
0.00 |
| 2011-09-30 |
$0.00B |
$0.02B |
0.00 |
| 2011-06-30 |
$0.00B |
$0.01B |
0.00 |
| 2011-03-31 |
$0.00B |
$0.02B |
0.00 |
| 2010-12-31 |
$0.00B |
$0.02B |
0.00 |
| 2010-09-30 |
$0.00B |
$0.01B |
0.00 |
| 2010-06-30 |
$0.00B |
$0.01B |
0.00 |
| 2010-03-31 |
$0.00B |
$0.01B |
0.00 |
| 2009-12-31 |
$0.00B |
$0.01B |
0.00 |
| 2009-09-30 |
$0.00B |
$0.01B |
0.00 |
| 2009-06-30 |
$0.00B |
|
0.00 |
| 2009-03-31 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED PRODUCTS |
$0.409B |
$0.000B |
|
Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.
|
